Introduction
============

The development of psychopharmacological treatments for psychiatric disorders has made physical interventions less popular, evidenced by the marked decline in neurosurgery since its hey-day in the 1960s. Many psychiatric patients are resistant to medications or are unable to tolerate their side-effects, and therefore novel treatments for neuropsychiatric disorders are necessary. In the last decade, several new physical treatments have been introduced that hold the potential to join the mainstream of psychiatric therapy. In this paper we review the efficacy of transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) and the current status of neurosurgery which, although not new, continues to be novel among neuropsychiatric treatments. Light therapy was excluded from this review as much of the literature pertaining to it is linked with seasonal affective disorder and it does not generally come under the rubric of "physical treatments" in neuropsychiatry.

Method
======

The literature was reviewed selectively by entering the search terms "transcranial magnetic stimulation", "vagus nerve stimulation", "deep brain stimulation", "psychosurgery", and "neurosurgery" into MEDLINE, EMBASE, and PSYCHLIT. To identify more-specific articles the names of some of the surgical procedures, eg, "stereotactic subcaudate tractotomy", "capsulotomy", "limbic leucotomy", and "cingulotomy", were entered. As few randomized controlled trials have been possible or indeed attempted using VNS, DBS, and neurosurgery, the use of strict criteria such as inclusion of placebo or blinding status was not possible and studies were hence included based on their clinical salience. We also included industry-sponsored trials as although these include an interest on the part of the sponsor, they have withstood quality control and audit by bodies such as the FDA and often have attracted the largest numbers of participants.

Transcranial magnetic stimulation (TMS)
=======================================

TMS is performed by placing an electromagnetic coil on the scalp through which large currents are pulsed to generate rapidly fluctuating magnetic fields. These cross the scalp unimpeded and generate eddy currents in the underlying brain cortex that depolarise neurons and produce an associated effect ([@b147-ndt-2-165]) (see [Figure 1a](#f1-ndt-2-165){ref-type="fig"}). The neural response is contingent upon a number of variables, such as the site of application, the stimulation parameters, and the use of single or multiple stimuli ([@b24-ndt-2-165]). The application of repeated TMS pulses to a particular site is termed repetitive TMS (rTMS) and the application at frequencies above 1Hz is referred to as fast-frequency repetitive TMS (FF-rTMS). The latter has been most investigated in neuropsychiatric treatment studies.

TMS in neuropsychiatric disorders
---------------------------------

The rapid and widespread implementation of TMS over the last 20 years has generated considerable debate about the effects and implications of using this noninvasive method of brain stimulation.

### Depression

In preclinical studies with rats TMS shows an effect similar to that produced by antidepressants and electroconvulsive shock ([@b11-ndt-2-165]; [@b100-ndt-2-165]; [@b86-ndt-2-165]; [@b97-ndt-2-165]). There have also been findings that support it having an antidepressant action in humans, including reports that it delays the onset of rapid eye movement (REM) sleep in healthy subjects ([@b21-ndt-2-165]) and normalizes the dexamethasone suppression test in depressed patients ([@b141-ndt-2-165]).

Guided by neuroimaging studies, the prefrontal cortex was proposed as a suitable target for antidepressant rTMS ([@b47-ndt-2-165]), and initial studies of focal rTMS of the left prefrontal cortex (PFC) seemed encouraging ([@b136-ndt-2-165]). Comparison across studies has been difficult because of differences in patient populations, study design, duration, and rTMS parameters. A summary of sham-controlled treatment trials of rTMS is shown in [Table 1](#t1-ndt-2-165){ref-type="table"}.

There have been several meta-analyses of these placebo-controlled trials of rTMS for major depression. The Cochrane Collaboration ([@b115-ndt-2-165]) concluded that two weeks of high-frequency rTMS to the left dorsolateral prefrontal cortex led to significant improvement on the Hamilton Depression Rating Scale (HDRS) ([@b63-ndt-2-165]), but not on a self-rating scale such as Beck ([@b9-ndt-2-165]). This improvement was not sustained at 2-week follow-up. The authors concluded that the published evidence for an antidepressant effect of rTMS was weak. [@b16-ndt-2-165] conducted an independent meta-analysis of treatment studies, which included controlled and uncontrolled, blind, and open study designs. Analysis of effects in uncontrolled studies found a consistent but modest treatment effect (37% mean reduction in HDRS) and for controlled studies the magnitude of change was even smaller (27% mean reduction in HDRS for TMS group, compared with 7% reduction for sham treatment). In summary, meta-analyses show that statistical evidence for the efficacy of rTMS is fairly robust but that clinical outcomes are modest. An important caveat, though, is that most of the trials to date have only compared rTMS to a sham control over a 2-week period, whereas evidence from trials allowing longer treatment periods, either in an open extension (eg, [@b103-ndt-2-165]) or within the controlled phase ([@b150-ndt-2-165]), suggests further improvement occurs with increasing duration of rTMS.

A number of studies randomized depressed subjects to receive electroconvulsive therapy (ECT) or 4 weeks of rTMS. These reported a clear advantage ([@b60-ndt-2-165]) or emerging trends ([@b142-ndt-2-165]; [@b80-ndt-2-165]) in favour of ECT, though one study found no difference ([@b61-ndt-2-165]). Of interest, the results of [@b60-ndt-2-165] suggested that rTMS may be equally effective as ECT for treating nonpsychotic depression, but had little efficacy in psychotic depression.

Investigators in the field concur that there still remains a need for large multi-center trials with longer sham-controlled periods and greater scientific rigor including appropriate and documented randomization and assessment as well as increased monitoring of both the patient and the therapeutic characteristics that modulate treatment outcome ([@b75-ndt-2-165]).

Another experimental application of TMS has been magnetic seizure therapy (MST), the use of rTMS at high stimulus frequency and intensity to deliberately induce a generalized seizure under anesthesia for the treatment of depression ([@b126-ndt-2-165]). MST stimulation is more focal than that of ECT, thus leading to the expectation of fewer cognitive side effects. So far, preliminary trials in nonhuman primates and human subjects have confirmed this expectation, while case reports have found that MST led to significant improvement in two medication-resistant depressed subjects ([@b126-ndt-2-165]).

### Bipolar disorder

There have been a number of case reports of the induction of mania in depressed subjects receiving rTMS treatment ([@b45-ndt-2-165]; [@b36-ndt-2-165]; [@b156-ndt-2-165]; [@b170-ndt-2-165];[@b67-ndt-2-165]). [@b58-ndt-2-165] published the first trial of rTMS for the treatment of acute mania, randomizing patients to receive high-frequency rTMS to the left or right prefrontal cortices. Right prefrontal stimulation appeared to have an antimanic effect with 71% mean improvement on the Young Mania Rating Scale ([@b182-ndt-2-165]), whereas left prefrontal stimulation was associated with 29% mean improvement. Taken together with the results of depression trials demonstrating efficacy for high-frequency left prefrontal rTMS, these findings suggest that rTMS to the left and right prefrontal cortices respectively may have opposing effects. In further open studies, [@b154-ndt-2-165] and [@b119-ndt-2-165] also reported that rTMS may be a useful add-on treatment to medication in acute mania. However, the only sham-controlled study of rTMS in mania, which used the exact same rTMS parameters as in the study by [@b58-ndt-2-165], failed to find any advantage for right prefrontal rTMS over sham ([@b84-ndt-2-165]).

### Schizophrenia

Left prefrontal high-frequency rTMS and right prefrontal low-frequency rTMS have also been trialled as treatments in patients with schizophrenia ([@b22-ndt-2-165]; [@b88-ndt-2-165]; [@b148-ndt-2-165]; [@b62-ndt-2-165]; [@b74-ndt-2-165]). Results have shown variable degrees of improvement in positive and negative symptoms and in mood. The inconsistent findings of the sham-controlled studies ([@b88-ndt-2-165]; [@b148-ndt-2-165]; [@b62-ndt-2-165]; [@b74-ndt-2-165]) can perhaps be partly explained by the effect of interaction in that daily attendance required by the rTMS treatment protocol may have accounted for some of the changes observed, particularly any reduction in negative symptoms.

Some sham-controlled studies have reported that slow TMS over the left auditory cortex can reduce auditory hallucinations ([@b72-ndt-2-165], [@b73-ndt-2-165]; [@b139-ndt-2-165]). Others have failed to find any significant effects ([@b107-ndt-2-165]; [@b163-ndt-2-165]) despite the use of individual fMRI to specifically identify and target the cortical sites for inner speech production, thought to be involved in the production of hallucinations. Some of the inconsistencies in findings may also be explained by a lack of consensus for rating of auditory hallucinations.

### Other psychiatric disorders

There have been preliminary reports examining the use of rTMS in the treatment of other psychiatric disorders such as obsessive-compulsive disorder (OCD) ([@b155-ndt-2-165]; [@b4-ndt-2-165]), post traumatic stress disorder ([@b58-ndt-2-165]; [@b106-ndt-2-165]; [@b23-ndt-2-165]), and Tourette's syndrome ([@b17-ndt-2-165]). There have also been reports of high-frequency rTMS exacerbating anxiety and panic ([@b55-ndt-2-165]) and low-frequency rTMS alleviating panic disorder ([@b186-ndt-2-165]). The role of rTMS in these disorders is at present unclear.

### Neurological disorders

TMS has been investigated particularly in patients with Parkinson's disease and epilepsy. In Parkinson's disease, rTMS has been administered in an attempt to treat bradykinesia and improve motor control. During movement, simultaneous stimulation of the motor cortex has been reported to be of no benefit ([@b52-ndt-2-165]) and stimulation of the supplementary motor area has been shown to worsen fine movements ([@b27-ndt-2-165]). Other studies stimulating the PFC have noted modest benefits ([@b167-ndt-2-165]; [@b165-ndt-2-165]; [@b166-ndt-2-165]), some researchers suggesting that rTMS can diminish bradykinesia and enhance motor speed ([@b167-ndt-2-165]; [@b166-ndt-2-165]).

Interestingly, the application of TMS is associated with a measurable risk of seizure induction and yet, paradoxically, it has been found to be relatively safe in patients with epilepsy ([@b171-ndt-2-165]). Indeed, it may in fact be an effective means of reducing seizure activity (Tegaru et al 1999; [@b117-ndt-2-165]; [@b180-ndt-2-165]), although further research is needed.

Investigational applications of TMS
-----------------------------------

In cognitive neuroscience TMS has proven to be a versatile and valuable investigational tool, and has been used to examine cortical excitability and various aspects of brain cognition. It has been applied to the motor cortex in humans to examine motor evoked potentials (MEP) and motor threshold (MT). MT is the stimulus intensity required to elicit MEP and in any given individual is relatively constant with interhemispheric differences, but is subject to modulation by drugs and disease.

### Paired pulse TMS (ppTMS)

Paired pulse TMS involves the application of a pair of stimuli separated by a variable inter-stimulus interval. The first stimulus is subthreshold whereas the second is above the threshold. Varying the inter-stimulus interval allows modulation of the overall response to the paired stimuli such that response can be facilitated or inhibited. Facilitation can usually be achieved with an inter-stimulus interval of 10--20 msec, and on either side of this (shorter or longer), inhibition is more likely. Neurochemically, inhibition and facilitation are mediated by gamma-amino butyric acid (GABA) and glutamate respectively.

When a TMS pulse elicits a MEP against a background of voluntary muscle contraction, the background activity is suppressed for a period after the MEP. This "silent period" is considered another measure of inhibitory cortical activity ([@b134-ndt-2-165]).

### Psychiatric disorders

The above TMS testing paradigms have been used to investigate abnormalities in cortical inhibitory and facilitatory processes in the motor cortex of patients with psychiatric disorders ([@b108-ndt-2-165]). In schizophrenia, abnormalities have been reported in the MEP response to single pulse TMS ([@b1-ndt-2-165]; [@b143-ndt-2-165]), and in silent period measurements and response to paired pulse stimulation ([@b30-ndt-2-165]; Fitzgerald et al 2001), suggesting a reduction in cortical inhibitory processes. However, these investigations were mostly done in medicated patients, and alterations in motor cortical functioning in the presence of antipsychotic medication have been demonstrated elsewhere ([@b185-ndt-2-165]; [@b135-ndt-2-165]).

Several studies have reported increased cortical inhibition ([@b169-ndt-2-165]) or reduced post-exercise cortical facilitation in depressed subjects ([@b158-ndt-2-165]; [@b164-ndt-2-165]), though others have reported that the latter findings appeared to be nonspecific, occurring also in patients with mania and schizophrenia ([@b19-ndt-2-165]). There are also preliminary reports of abnormalities in motor cortical functioning in OCD ([@b57-ndt-2-165]), and Tourette's syndrome ([@b185-ndt-2-165]).

### Cognition

TMS is increasingly being used in neuropsychological investigations (eg, [@b98-ndt-2-165]). During TMS or rTMS, functioning of the stimulated cortical area can be temporarily disrupted, creating in effect a "virtual lesion". This technique can then be applied to examine the cortical sites involved in a particular function and the critical time periods of their involvement ([@b137-ndt-2-165]). For example, rTMS can be used to noninvasively identify the lateralization of verbal functions (Epstein 1998). Studies of the frontal and prefrontal cortex have examined aspects of memory and word generation ([@b54-ndt-2-165]; [@b79-ndt-2-165]). For example, [@b34-ndt-2-165] have recently demonstrated that TMS-induced interference in the left inferior prefrontal cortex has an effect on semantic but not perceptual processing. TMS can also enhance neuropsychological functioning when administered to specific cortical areas with precise timing, eg, picture naming ([@b173-ndt-2-165]).

Clearly, this innovative field of research has expanded tremendously with the introduction of TMS as an investigative tool and is an area of research that is likely to yield many new insights into the functioning of the normal and diseased brain.

Overall, TMS remains a useful tool for the investigation of abnormal physiological processes in psychiatric disorders. Further research in larger samples of unmedicated subjects is needed before definitive conclusions can be made.

Adverse effects
---------------

TMS has few adverse effects as it is relatively noninvasive. The risks that are associated with its use are determined largely by the number, intensity, and frequency of stimuli applied. Occasionally, rTMS results in a headache that may last several hours. Some subjects complain of scalp discomfort during TMS, attributable to the associated stimulation of muscles and nerves near the coil. Low frequency TMS and ppTMS are unlikely to produce seizures, or have any lasting effects on cognition, but rTMS, by increasing cortical excitability, can precipitate seizures even in healthy subjects, though the risk is very low ([@b179-ndt-2-165]).

It is important to note that TMS can cause a temporary shift in auditory threshold and to protect patients from this during stimulation a set of precautionary earplugs should be worn ([@b179-ndt-2-165]).

Vagus nerve stimulation (VNS)
=============================

The vagus nerve or the Xth cranial nerve is a mixed nerve, composed predominantly of sensory afferents carrying information from the thorax, abdomen, head, and neck to the brain. Cell bodies of these vagus-sensory afferents lie predominantly in the nodose ganglion and project information primarily to the nucleus tractus solitarius (NTS) as well as the area postrema, the spinal trigeminal nucleus, the medullary reticular formation, the dorsal nucleus of the vagus, and the nucleus ambiguous ([@b70-ndt-2-165]). Information is conveyed via these direct projections and by an autonomic feedback loop to the rest of the brain and ascending projections to the forebrain which travel via the parabrachial nucleus and the locus coeruleus. These structures have direct connections with the forebrain, thalamus, hypothalamus, amygdala, and stria terminalis -- regions that are important in the modulation of mood ([@b48-ndt-2-165]; [@b174-ndt-2-165]). Vagus nerve projections attend brain regions that are thought to be involved in several neuropsychiatric disorders presenting the potential for VNS to have several important clinical roles in addition to its use in treating epilepsy and depression.

In humans, VNS involves stimulation of the left cervical vagus nerve using a commercial device -- the Neuro-Cybernetic Prosthesis (NCP) System ([@b159-ndt-2-165]). This device comprises a bipolar pulse generator, electrodes, and a programming wand. The generator is implanted in the left chest wall below the clavicle and delivers electrical signals via a bipolar lead to an electrode that is wrapped around the vagus nerve in the neck (see [Figure 1b](#f1-ndt-2-165){ref-type="fig"}). Implantation usually takes less than an hour and can be conducted under general or local anesthesia ([@b5-ndt-2-165]). On-line modification and data retrieval are possible as a proprietary instrument is used to program the pulse generator. The latter can be stopped briefly using a hand held magnet but stimulus interruption does not interfere with preprogrammed stimulation which automatically resumes when the magnet is displaced ([@b50-ndt-2-165]).

VNS reduces the excitability of neurons involved in the propagation of seizure activity ([@b183-ndt-2-165]); however, its exact mechanisms of action remain unknown though it is thought to produce slow hyperpolarization. EEG and neuroimaging data, using single photon emission computed tomography, implicate the thalamus ([@b146-ndt-2-165]; [@b177-ndt-2-165]), inhibition of which may prevent the onset or propagation of seizures ([@b175-ndt-2-165]).

Efficacy
--------

To date, the main use of VNS has been to reduce seizure frequency in both adults ([@b10-ndt-2-165]; [@b64-ndt-2-165]; [@b127-ndt-2-165]; [@b178-ndt-2-165]) and children ([@b138-ndt-2-165]; [@b178-ndt-2-165]) with treatment-resistant epilepsy. Improvements gained appear to be sustained and may continue with time ([@b157-ndt-2-165]; [@b31-ndt-2-165]).

Two studies have shown an improvement in mood in epileptic patients receiving VNS compared with controls ([@b66-ndt-2-165]; [@b76-ndt-2-165]) and such observations have led researchers to hypothesize that it may be effective in treating mood disorders ([@b66-ndt-2-165]; [@b38-ndt-2-165]). The fact that it increases central noradrenergic and serotonergic neurotransmission would be in keeping with such a hypothesis ([@b93-ndt-2-165]; [@b82-ndt-2-165]), and in common with other effective antidepressant therapies it alters limbic system blood flow, involving in particular the cingulate ([@b69-ndt-2-165]).

Open studies to examine the effects of VNS on mood have been conducted in treatment-resistant depressed patients ([@b151-ndt-2-165]; Sackeim et al 2001). In a multi-center study, 30 depressed patients (n = 21; nonpsychotic treatment-resistant major depression, n = 4; bipolar, and n = 5 bipolar II) underwent 10 weeks of VNS after which 40% of patients reported having a significant reduction in mood-scale scores (Ham-D and MADRS). These findings were sustained during long-term follow-up ([@b151-ndt-2-165]). Further preliminary studies ([@b92-ndt-2-165]) also suggest that VNS has antidepressant properties; however, there is a need for larger controlled trials and at least one is currently underway ([@b161-ndt-2-165]). Several recently published studies provide preliminary support for VNS having an antidepressant role. Firstly, in a multicenter trial [@b152-ndt-2-165] compared the effects of 10 weeks' active as opposed to sham VNS in 222 participants with treatment-resistant depression. They found VNS was linked with greater symptom reduction across measures but the finding did not reach significance and hence could not be considered definitive evidence of its efficacy. This group subsequently published further results of a one-year open trial involving patients who had completed the initial acute phase ([@b153-ndt-2-165]). The results from 205 participants in this study revealed statistically significant reduction in depressive symptoms and despite the lack of a control group and nonmasking of ratings, these data seem to support further investigation of VNS as an antidepressant. Finally, [@b51-ndt-2-165] compared the results from the one-year open trial with the results from a comparable treatment-as-usual (TAU) group. The primary analysis in this study yielded a significant difference between the groups favoring VNS plus TAU over TAU alone. The addition of VNS to TAU resulting in improved response supports its role as an antidepressant, although this still requires further investigation.

VNS was initially approved in the US by the FDA for the treatment of epilepsy in 1997 and just recently (July 2005) the VNS therapy system has been approved to treat depressed patients of 18 years and over who have not had a response to four or more trials of an antidepressant ([@b28-ndt-2-165]). It has also been approved for use in the treatment of depression in the EU and Canada. It would be useful to extend VNS trials to include depressed patients other than those who are treatment resistant, in order to examine its differential efficacy across depressive subtypes and also its effects on cognition ([@b160-ndt-2-165]).

Adverse effects
---------------

The adverse effects of VNS are, firstly, those associated with the procedure of implantation and, secondly, those that occur as a consequence of stimulation. Surgical adverse effects include pain, coughing, left-vocal cord paralysis, hoarseness, nausea, and very occasionally infection. Most patients describe these as a moderate inconvenience and the effects are usually transient ([@b159-ndt-2-165]). Of note, during implantation, there have been no deaths and no reports of serious adverse events such as the alteration of cardiac or pulmonary function. However, transient asystole has occurred in a small number of patients when the stimulator is first activated during in-theatre testing. The most significant stimulation-related adverse effects are those of dyspnea and voice-alteration ([@b18-ndt-2-165]), which can be reversed by application of the hand-held magnet and prevented by lowering the stimulation current ([@b159-ndt-2-165]).

Deep brain stimulation (DBS)
============================

In the management of Parkinson's disease (PD) and other movement disorders DBS is an important treatment that appears to have an additional antidepressant effect without causing any global cognitive deterioration ([@b43-ndt-2-165]). In PD, neural degeneration and transmitter deficiencies lead to neural dysfunction and abnormal activity in motor system relays such as the thalamus, the internal segment of the globus pallidus (GPi) ([@b120-ndt-2-165]), and the subthalamic nucleus (STN) ([@b181-ndt-2-165]), with the last emerging as the most popular target for treatment interventions ([@b15-ndt-2-165]).

Using implanted quadripolar electrodes connected to a battery-powered pulse-generating device (see [Figure 1](#f1-ndt-2-165){ref-type="fig"}), DBS delivers an electrical current, the strength of which can be adjusted by varying electrode selection and polarity and by altering frequency, amplitude and pulse-width. In the treatment of PD, parameters that are typically used include a voltage of more than 3 V with a pulsewidth of 60--90 μsec and a frequency of 150--185 Hz ([@b104-ndt-2-165]).

The mechanism of action of DBS, like other physical treatments, is unknown but both clinical and experimental evidence indicate that the frequency of stimulation affects clinical outcome. [@b15-ndt-2-165] outline the main hypotheses that account for the benficial effects of high frequency stimulation as follows: the effect is due to depolarization blocking neuronal transmission through inactivation of voltage-dependent ion channels; the jamming of information imposes an efferent stimulation-driven high frequency pattern; stimulation of inhibitory afferents results in synaptic inhibition to the target nucleus; and stimulation induces neurotransmitter depletion, and hence causes synaptic depression. This explanation is corroborated to some extent by animal models of PD in which there is increased basal spontaneous activity in the STN that drives GPi nucleus inhibitory outflow. The outflow in turn inhibits motor systems within the thalamus, brainstem, and cortex and results in the akinesia and bradykinesia of PD ([@b32-ndt-2-165]). Hence the rationale for surgical intervention is to interrupt the excessive inhibition from these nuclei ([@b96-ndt-2-165]). Electrical stimulation achieves this by producing neuronal inactivation either by direct disruption of neuronal activity or by increasing GABA-mediated inhibitory neurotransmission. Interestingly, the afferents that impinge upon neurones in the GPi nucleus and STN are rich in GABA (see [Figure 1c](#f1-ndt-2-165){ref-type="fig"}).

Indications for DBS in PD include advanced idiopathic illness with motor complications, tremor, and related disability. With GPi or STN DBS the symptoms of PD can be improved by up to 80% and in many cases the use of concurrent medications can be significantly reduced if not stopped altogether ([@b99-ndt-2-165]; [@b176-ndt-2-165]). Vim thalamus DBS has a greater specificity of action and is effective in alleviating the tremor of PD in up to 80% of patients; however, unlike DBS applied to the GPi and STN, it fails to produce significant functional improvement and has few additional benefits ([@b162-ndt-2-165]) such as alleviating motor fluctuations, bradykinesia, gait disturbances, and drug-induced dyskinesias. Not surprisingly, GPi and STN DBS are being increasingly favored and there is now almost no indication for Vim thalamus DBS as these treatments are far superior in effect. The disadvantage of this trend is that speech and cognition are less responsive and some of the problems that patients face can in fact be exacerbated by surgery ([@b99-ndt-2-165]).

Efficacy
--------

As a treatment DBS has the advantage of being precise and reversible ([@b56-ndt-2-165]), a clear advance in comparison to neurosurgery for intractable psychiatric disorders ([@b145-ndt-2-165]; [@b91-ndt-2-165]). Furthermore, the strength of stimulation can be controlled allowing treatment to be adjusted according to individual needs, which has made it an increasingly popular choice for the treatment of refractory PD.

DBS has also been found to be beneficial in two of three cases of treatment refractory OCD described by [@b44-ndt-2-165]. [@b6-ndt-2-165] describe DBS of the ventral caudate nucleus as effective in improving functioning and achieving remission in a patient with intractable severe OCD and concomitant major depression. [@b105-ndt-2-165] report an increase in the number of applications for DBS, indicating recognition of its potential for treating neuropsychiatric disorders as well as its continued importance in the treatment of movement disorders.

Adverse effects
---------------

Predictably, the adverse effects associated with DBS are largely the consequence of surgery as opposed to stimulation. One of the most common side-effects is that of transient confusion; More serious side-effects can also occur although the likelihood is less than 2%. Stimulation is also associated with speech disturbance, paraesthesiae, eye movement difficulties, and motor contractions. Complications can also arise because of device failure; however, this is easily remedied by replacement of the necessary components.

Neurosurgery
============

Psychosurgery has been "practised" since antiquity involving trephination thought to release "evil spirits". At the beginning of the twentieth century neurosurgery experienced a resurgence of interest; however, the development of psychotropic medications largely eliminated the need for standard prefrontal leucotomy ([@b42-ndt-2-165]), which was used to "treat" schizophrenia and affective psychoses ([@b172-ndt-2-165]*).* However, neurosurgery for mental disorders has survived in modified form and in many parts of the world remains a treatment option for neuropsychiatric illnesses where all other options have been exhausted.

Modern-day neurosurgical procedures, although more refined and sophisticated, continue to target the limbic system and its connections, particularly frontal lobe circuits that involve striatal structures such as the thalamus and caudate ([@b26-ndt-2-165]). Currently, four neurosurgical procedures are performed worldwide namely: cingulotomy, stereotactic subcaudate tractotomy (SST), anterior capsulotomy (AC), and limbic leucotomy (LL) ([@b111-ndt-2-165]), with the last in essence combining the lesions of the first two ([@b87-ndt-2-165]) (see [Figure 1d](#f1-ndt-2-165){ref-type="fig"}). The indications, ablative techniques, lesion sites, and targets of these procedures are summarized in [Table 2](#t2-ndt-2-165){ref-type="table"}.

It is noteworthy that all three neurosurgical lesions interrupt the interconnecting pathways of the limbic system and the prefrontal cortex, in particular the amygdalofugal pathways and those of the limbic loop, explaining perhaps the overlapping effects of these procedures.

Efficacy
--------

Psychosurgery for psychiatric disorders is almost always considered a treatment of last resort and as a consequence psychiatric patients that undergo surgical procedures are by definition treatment refractory. Nevertheless, in countries where these procedures are available, strict regulations govern the selection and consent of patients to ensure that all reasonable alternatives have been adequately explained ([@b20-ndt-2-165]).

In the treatment of OCD, psychosurgery has been reasonably effective with significant improvement in 40%--60% of cases undergoing anterior capsulotomy ([@b123-ndt-2-165]; [@b122-ndt-2-165]; [@b144-ndt-2-165]). In comparison, SST has generally been less helpful in OCD, with improvement occurring in only a third of patients ([@b71-ndt-2-165]); however, it is effective in mood disorders, with more than a third of patients achieving a good outcome ([@b71-ndt-2-165]; [@b112-ndt-2-165]; [@b140-ndt-2-165]; [@b110-ndt-2-165]). Recently, the mechanism of action of SST in depression has been investigated ([@b29-ndt-2-165]), with improvement thought to occur by way of an acquired insensitivity to negative information. This interesting but provocative suggestion warrants further investigation.

In addition to its use in OCD, capsulotomy has also been used to treat refractory social phobia, generalized anxiety disorder, and panic disorder. Long term it appears to produce a notable reduction in anxiety, with 67% of subjects showing significant response ([@b149-ndt-2-165]); however, concerns have been raised as to whether the procedure causes frontal lobe dysfunction, which may be masked by seeming improvement.

In contrast to capsulotomy and SST, cingulotomy introduced by Fulton and refined by Ballantine et al (1997) ([@b116-ndt-2-165]) has been used almost exclusively to treat OCD with reasonable success in approximately one third of patients ([@b81-ndt-2-165]), and because of the conservative nature of the procedure many patients benefit from a second operation to extend the original lesion. However, worsening of obsessionality has also been described, with one study reporting pre-operative obsessive traits predisposing epileptic patients to develop OCD ([@b94-ndt-2-165]).

Limbic leucotomy has been less widely used than the other procedures but has been utilized to treat a broad range of symptoms with modest success (treatment response of 36%--50%) in patients with major depression and OCD ([@b125-ndt-2-165]).

Adverse effects
---------------

All surgery confers some degree of risk and this is particularly true of neurosurgery in as the operation involves structural reorganization of cortical matter. The most common complaints following SST are confusion, a transient lack of sphincter control, and lethargy, with the latter persisting beyond one week in 12% of patients ([@b111-ndt-2-165]). These are similar to the adverse effects associated with AC except that no deaths have been reported and documented seizures have been rare. Similarly, cingulotomy has not resulted in any reported deaths, and reports of seizures are scarce; however, it has caused two cases of hemiplegia ([@b7-ndt-2-165]; [@b114-ndt-2-165]).

Despite the relative safety of these procedures, concerns remain about the effects of neurosurgical procedures on personality and behaviour ([@b65-ndt-2-165]) and there is some evidence to suggest that frontal lobe deficits such as disinihibition, apathy, and cognitive inflexibility have occurred following cingulotomy ([@b78-ndt-2-165]; [@b149-ndt-2-165]). [@b25-ndt-2-165] also found no differences between post-surgical patients and controls on tests of memory and global ability; however, there were deficits present in formation and shifting of set. [@b12-ndt-2-165] makes the point that many patients are asked to self-report on symptoms post-operatively and that the validity of information gathered in this context is questionable, especially if patients have compromised frontal lobe function.

Discussion
==========

Limited knowledge of the neuropsychiatric disorders themselves, as well as the mechanisms underpinning physical treatments, continues to hamper growth in this field that is further constrained by a tendency for polarization of opinions in relation to its evidence base and ethics. Thus far, TMS is the only physical treatment that has acquired a firm footing, with studies demonstrating its efficacy in the treatment of depression. Equally valuable is its application into research where it has been used to create "virtual lesions". Its relative noninvasiveness and acceptance by patients have made it a popular therapy.

More invasive treatments such as DBS and VNS offer greater control than neurosurgery by allowing stimulation to be titrated to achieve an optimal response. In some cases the specificity of these interventions makes them preferable to pharmacotherapy which, although more widely acceptable, is relatively blunt as regards site of action and timing of effect. With respect to the latter, DBS produces effects over a matter of milliseconds, in tune with the electrophysiology of the brain. It is therefore potentially capable of mimicking normal physiological function and its use in the management of PD has paved the way for wider application. Initial studies of its efficacy in the treatment of refractory psychiatric illnesses are encouraging. Similarly, the application of VNS has expanded beyond its role as an "anticonvulsant" to studies examining its antidepressant properties. A recent study indicated 15.5% of patients with treatment-resistant depression achieved sustained remission compared with 4.6% of the participants receiving treatment as usual ([@b51-ndt-2-165]). Recently, it has been approved as an antidepressant treatment in the EU and Canada, and this opens up the possibility of its application in a range of psychiatric illnesses including pain syndromes, addictions, and eating disorders.

Somewhat surprisingly neurosurgery has regained popularity as an effective treatment for refractory psychiatric disorders, even though it is still considered only following the failure of traditional methods. Part of the reason for this is its apparent success in a patient population that has a very low rate of placebo response. However, psychosurgical research has been plagued by the lack of standardized nosology and the inherent referral bias, as patients undergoing such procedures are clearly not representative of the respective phenotypes to which they belong. Clearly, the fact that few procedures are performed and they are necessarily invasive limits the prospects of sham-controlled prospective studies. Improvements in technology and surgical techniques with increasing sophistication of instrumentation will likely make such studies possible in the future. However, in the interim research along the lines of [@b29-ndt-2-165] has shed light on the specific cognitive processes altered by such procedures and is likely to inspire greater clinical confidence.

Conclusion
==========

In the past decade physical interventions have once again captured the imagination of neuroscientists and clinicians alike. However, in comparison with pharmacological treatments they remain under-researched due to a range of political, economic, and sociological factors. It is also difficult to compare efficacy rates of pharmacologically treated patients with those who receive physical interventions as the characteristics of the two groups vary substantially in terms of resistance, duration of illness, and prior treatment. Despite this, these treatments provide novel insights into the neurobiology of these neuropsychiatric disorders and interventions such as TMS are beginning to establish themselves as viable therapeutic options. However, if history is not to repeat itself, the field has to be cautious in its predictions and claims. Key advances in neuroimaging, for instance, have ensured much better localization and monitoring of the effects of these interventions but the longer-term effects have yet to be determined. In reality, each of the physical treatments described requires much further clinical investigation. Fortunately, this is at last a possibility and many researchers have taken up the challenge. It is hoped that in the coming decade some of these interventions in their modified forms will become more widely accepted as mainstream treatments and benefit the many patients with intractable neuropsychiatric disorders.

![Illustration of brain regions affected by the physical treatments transcranial magnetic stimulation (a), vagus nerve stimulation (b), deep brain stimulation (c), and neurosurgery (d).\
**Abbreviations:** NCP, neurocybernetic prosthesis.](ndt-2-165f1){#f1-ndt-2-165}

###### 

TMS/sham controlled studies

  Study               N                Design/RTMS treatment                                                                                                                                              Mean % change HDRS[4](#tfn4-ndt-2-165){ref-type="table-fn"}   Number of responders[5](#tfn5-ndt-2-165){ref-type="table-fn"}
  ------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------------
  [@b136-ndt-2-165]   17               Multiple crossover: L and R DLPFC (active/sham), vertex (active) 10 Hz[1](#tfn1-ndt-2-165){ref-type="table-fn"}, 5 days[2](#tfn2-ndt-2-165){ref-type="table-fn"}   L DLPFC active: 48%,                                          L DLPFC active: 4
                      Other: 4%--12%   Other: 0                                                                                                                                                                                                                         
  [@b48-ndt-2-165]    12               Crossover: L DLPFC (active/sham), 20 Hz, 10 days                                                                                                                   Active: 16%                                                   Active: 1
                                                                                                                                                                                                          Sham: 13%↑                                                    Sham: 0
  [@b103-ndt-2-165]   18               Parallel: L DLPFC (active/sham), 10 Hz, 10 days                                                                                                                    Active: 23%                                                   Active: 0
                                                                                                                                                                                                          Sham: 25%                                                     Sham: 1
  [@b133-ndt-2-165]   18               Parallel: L DLPFC (active) 10 Hz/0.3 Hz, (sham) 10 Hz, 5 days                                                                                                      10 Hz: 6%                                                     All: 0
                                       0.3 Hz: 19%                                                                                                                                                                                                                      
                                                                                                                                                                                                          Sham: 6% ↑                                                    
  [@b88-ndt-2-165]    70 dep           Parallel: R DLPFC (active/sham), 1 Hz, 10 days                                                                                                                     Active: 47%                                                   Active: 17/35
                                                                                                                                                                                                          Sham: 22%                                                     Sham: 8/32
  [@b13-ndt-2-165]    20               Parallel: L DLPFC (active/sham), 20 Hz, 10 days                                                                                                                    Active: 39%                                                   Active: 1
                                                                                                                                                                                                          Sham: 0.5%                                                    Sham: 0
  [@b39-ndt-2-165]    12               Crossover: L DLPFC (active/sham), 10 Hz, 5 days                                                                                                                    Active: 22%                                                   ?[6](#tfn6-ndt-2-165){ref-type="table-fn"}
                                                                                                                                                                                                          Sham: 7% ↑                                                    
  [@b49-ndt-2-165]    30               Parallel: L DLPFC (active) 20 Hz/5 Hz, (sham) 20 Hz/5 Hz, 10 days                                                                                                  20 Hz: 26%                                                    20 Hz: 3
                                       5 Hz: 48%                                                                                                                                                          5 Hz: 6                                                       
                                                                                                                                                                                                          Sham: 21%                                                     Sham: 0
  [@b46-ndt-2-165]    28               Parallel: L DLPFC (active/sham), 20 Hz, 10 days                                                                                                                    Active: 38%                                                   Active: 4
                                                                                                                                                                                                          Sham: 34%                                                     Sham: 3
  [@b101-ndt-2-165]   36               Parallel: L DLPFC (active) 10 Hz, R DLPFC (sham) 1 Hz                                                                                                              L DLPFC: 21%                                                  ?
                                       R DLPFC: 20%                                                                                                                                                                                                                     
                                                                                                                                                                                                          Sham: 13%                                                     
  [@b113-ndt-2-165]   20               Parallel: L DLPFC (active/sham), 20 Hz, 5 days                                                                                                                     Active: 37%                                                   Active: 3
                                                                                                                                                                                                          Sham: 32%                                                     Sham: 3
  [@b35-ndt-2-165]    20               Parallel, 10 days                                                                                                                                                  Active: 29%                                                   ?
                                                                                                                                                                                                          Sham: 17%                                                     
  [@b132-ndt-2-165]   30               Parallel: L DLPFC (active) 100% MT[3](#tfn3-ndt-2-165){ref-type="table-fn"}, 90% MT, (sham) 10 Hz, 10 days                                                         100%: 30%                                                     100%: 3
                                       90%: 15%                                                                                                                                                           90%: 2                                                        
                                                                                                                                                                                                          Sham: 7%                                                      Sham: 0
  [@b102-ndt-2-165]   19               Parallel: Bilateral prefrontal (active/sham), 15 Hz, 15 days                                                                                                       Active: 24%                                                   Active: 2
                                       Sham: 21%                                                                                                                                                          Sham: 1                                                       
  [@b129-ndt-2-165]   23               Parallel: L DLPFC (active/sham), 5 Hz, 10 days                                                                                                                     Active: 25%                                                   Active: 4
                                                                                                                                                                                                          Sham: 25%                                                     Sham: 4
  [@b77-ndt-2-165]    30               Parallel: L DLPFC (active) 20 Hz, R 1 Hz, (sham) L 20 Hz, 10 days                                                                                                  L 20 Hz: 17%                                                  L 20 Hz: 5
                                       R 1 Hz: 10.5%                                                                                                                                                      R 1 Hz: 3                                                     
                                                                                                                                                                                                          Sham: 23%                                                     Sham: 5
  [@b41-ndt-2-165]    60               Parallel: L DLPFC (active) 10 Hz, R DLPFC 1 Hz, (sham) L 10 Hz/R 1 Hz, 10 days                                                                                     MADRSL 10 Hz: 13.5%                                           L 10 Hz: 8
                                       R 1 Hz: 15%                                                                                                                                                        R 1 Hz: 7                                                     
                                                                                                                                                                                                          Sham: 0.76%                                                   Sham: 2
  [@b83-ndt-2-165]    20               Parallel: L DLPFC (active/sham) 10 Hz, 10 days                                                                                                                     Active: 38%                                                   Active: 3
                                                                                                                                                                                                          Sham: 13%                                                     Sham: 0
  [@b85-ndt-2-165]    12               Parallel: R DLPFC (active/sham) 1 Hz, 10 days                                                                                                                      Active: 48%                                                   Active: 4
                                                                                                                                                                                                          Sham: 30%                                                     Sham: 2
  [@b75-ndt-2-165]    15               Parallel: L DLPFC (active/sham) 10 Hz, 10 days                                                                                                                     Active: 32%                                                   Active: 2
                                                                                                                                                                                                          Sham: 28%                                                     Sham: 1
  [@b128-ndt-2-165]   24               Parallel: L DLPFC (active/sham) 20 Hz, 10 days                                                                                                                     Active: 20%                                                   Active: 4
                                                                                                                                                                                                          Sham: 17%                                                     Sham: 0
  [@b67-ndt-2-165]    41               Parallel: L DLPFC (active) 20 Hz, L DLPFC 20 Hz + R DLPFC 1 Hz, (sham) L 20 Hz + R 1 Hz, 10 days                                                                   Active (both groups):                                         ?
                                       30.6%                                                                                                                                                                                                                            
                                       Sham: 24.8%                                                                                                                                                                                                                      
  [@b90-ndt-2-165]    55               Parallel: L DLPFC (active/sham), 20 Hz,10 days                                                                                                                     Active: 18.5%                                                 ?
                                                                                                                                                                                                          Sham: 15.4%                                                   
  [@b150-ndt-2-165]   46               Parallel: L DLPFC (active/sham) 5 Hz, 20 days                                                                                                                      Active: 57%                                                   Active: 21
                                                                                                                                                                                                          Sham: 35%                                                     Sham: 11

Hz, frequency of TMS pulses.

days, duration of TMS treatment in sham-controlled period.

\% MT, % of subject's resting MT.

Decreases in HDRS ([@b63-ndt-2-165]) scores except where otherwise indicated.

Defined as ≥ 50% decrease in HDRS from baseline.

information not available.

**Abbreviations:** L DLPFC, left dorsolateral prefrontal cortex; MADRS, Montgomery Asberg Depression Rating Scale ([@b124-ndt-2-165]); R DLPFC, right dorsolateral prefrontal cortex; TMS, transcranial magnetic stimulation; MT, motor threshold.

###### 

Neurosurgical procedures used in the treatment of neuropsychiatric disorders

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neurosurgical procedure   Indications                                       Ablative technique                                                                                       Lesion                                                                            Target
  ------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------------------
  Anterior capsulotomy      OCD and anxiety disorders                         Gammacapsuolomy (gamma knife focuses 200+ beams of cobalt^60^ gamma radiation upon a designated point)   Anterior limb of internal capsule (between head of caudate nucleus and putamen)   Neuronal tracts connecting thalamus and orbito-frontal cortex

  SST                       Affective disorders\                              Radiofrequency electrocoagulation supplanted yttrium in 1997                                             White matter beneath and just anterior to the head of the caudate nucleus         Fibres connecting prefrontal cortex and dorsomedial nucleus of thalamus
                            (UP/BP)\                                                                                                                                                                                                                                     
                            Anxiety Disorders\                                                                                                                                                                                                                           
                            OCD                                                                                                                                                                                                                                          

  Cingulotomy               OCD (primarily) and affective/anxiety disorders   Radiofrequency thermocoagulation                                                                         Cingulum (1 cm in width extending 2 cm dorsally from the corpus callosum)         Thalamofrontal neuronal loops
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After [@b89-ndt-2-165]; [@b168-ndt-2-165]; [@b14-ndt-2-165]; [@b130-ndt-2-165]; [@b53-ndt-2-165]; [@b8-ndt-2-165]; [@b2-ndt-2-165]; [@b7-ndt-2-165]; [@b118-ndt-2-165]; [@b3-ndt-2-165]; [@b81-ndt-2-165]; [@b121-ndt-2-165]; [@b33-ndt-2-165]; [@b37-ndt-2-165]; [@b114-ndt-2-165]; [@b131-ndt-2-165]; [@b109-ndt-2-165].

**Abbreviations:** BP, bipolar; OCD, obsessive-compulsive disorder; SST, stereotactic subcaudate tractotomy; UP, unipolar.
